Eris Lifesciences Limited (BSE: 540596, NSE: ERIS), one of India’s leading branded formulations companies, announced that a manufacturing unit at its Ahmedabad campus has received approval from ANVISA, Brazil’s national health regulatory agency. The approval comes after a successful inspection conducted in May 2025 and marks a major milestone as it allows Eris to enter Brazil, the largest pharmaceutical market in South America.
A company spokesperson highlighted that recognition from a stringent regulatory authority like ANVISA validates the strong GMP compliance and quality systems at Eris’ facilities. The same unit has already been inspected and cleared by several other global regulators earlier this year.
Founded in 2007, Eris Lifesciences is the youngest among India’s Top-20 pharmaceutical companies. The company reported FY25 revenue of ₹2,894 crore, with its branded formulations business crossing ₹3,000 crore in annual sales, according to AWACS. Over the last five years, revenue and operating profit have grown 2.6 times, supported by significant investments of around ₹4,000 crore in new technologies, therapeutic areas, and manufacturing expansion.
